Perrigo Company plc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Perrigo Company plc (PRGO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $15.40 million for the 9-month period ending 2025-09-27, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-11-05
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-27 was $14.10M, a 984.62% increase year-over-year.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-28 was $700.00K, a 97.02% decline year-over-year.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-29 was $600.00K, a 64.71% decline year-over-year.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-28 was $1.30M, a 51.85% decline year-over-year.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $73.90M, a 51.43% increase from fiscal 2021.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $48.80M, a 42.25% decline from fiscal 2020.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $84.50M, a 720.39% increase from fiscal 2019.
- Perrigo Company plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $10.30M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-27 | $14.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $14.80M derived: sum of 2 quarters · filed 2025-11-05 | $15.40M 10-Q · filed 2025-11-05 | |||||
| 2025-06-28 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.30M 10-Q · filed 2025-08-06 | ||||||
| 2025-03-29 | $600.00K 10-Q · filed 2025-05-07 | |||||||
| 2024-09-28 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $24.80M derived: sum of 2 quarters · filed 2025-11-05 | $26.50M 10-Q · filed 2025-11-05 | |||||
| 2024-06-29 | $23.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $25.20M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-30 | $1.70M 10-Q · filed 2025-05-07 | |||||||
| 2023-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.50M derived: sum of 2 quarters · filed 2024-11-06 | $5.90M 10-Q · filed 2024-11-06 | $17.50M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-07-01 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $3.20M 10-Q · filed 2024-08-02 | $14.80M derived: sum of 3 quarters · filed 2024-08-02 | $34.30M derived: sum of 4 quarters · filed 2024-08-02 | ||||
| 2023-04-01 | $1.40M 10-Q · filed 2024-05-07 | $13.00M derived: sum of 2 quarters · filed 2024-05-07 | $32.50M derived: sum of 3 quarters · filed 2024-05-07 | $43.70M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $31.10M derived: sum of 2 quarters · filed 2023-11-07 | $42.30M derived: sum of 3 quarters · filed 2023-11-07 | $73.90M 10-K · filed 2023-02-28 | ||||
| 2022-10-01 | $19.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $30.70M derived: sum of 2 quarters · filed 2023-11-07 | $62.30M 10-Q · filed 2023-11-07 | $68.60M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-07-02 | $11.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $42.80M 10-Q · filed 2023-08-08 | $49.10M derived: sum of 3 quarters · filed 2023-08-08 | $56.70M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-04-02 | $31.60M 10-Q · filed 2023-05-09 | $37.90M derived: sum of 2 quarters · filed 2023-05-09 | $45.50M derived: sum of 3 quarters · filed 2023-05-09 | $76.50M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $13.90M derived: sum of 2 quarters · filed 2023-02-28 | $44.90M derived: sum of 3 quarters · filed 2023-02-28 | $48.80M 10-K · filed 2023-02-28 | ||||
| 2021-10-02 | $7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $38.60M derived: sum of 2 quarters · filed 2022-11-08 | $42.50M 10-Q · filed 2022-11-08 | $102.50M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-07-03 | $31.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $34.90M 10-Q · filed 2022-08-09 | $94.90M derived: sum of 3 quarters · filed 2022-08-09 | $97.10M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-04-03 | $3.90M 10-Q · filed 2022-05-11 | $63.90M derived: sum of 2 quarters · filed 2022-05-11 | $66.10M derived: sum of 3 quarters · filed 2022-05-11 | $83.50M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $62.20M derived: sum of 2 quarters · filed 2022-03-01 | $79.60M derived: sum of 3 quarters · filed 2022-03-01 | $84.50M 10-K · filed 2022-03-01 | $86.90M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $19.60M derived: sum of 2 quarters · filed 2021-11-12 | $24.50M 10-Q · filed 2021-11-12 | $26.20M 10-Q · filed 2020-11-05 | $29.50M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-27 | $17.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $22.30M 10-Q · filed 2021-08-11 | $23.10M 10-Q · filed 2020-08-05 | $27.30M derived: sum of 3 quarters · filed 2021-08-11 | $19.80M derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-28 | $4.90M 10-Q · filed 2021-05-12 | $5.50M 10-Q · filed 2020-05-05 | $9.90M derived: sum of 2 quarters · filed 2021-05-12 | $2.40M derived: sum of 3 quarters · filed 2021-05-12 | $10.50M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$2.50M derived: sum of 2 quarters · filed 2021-03-01 | $5.60M derived: sum of 3 quarters · filed 2021-03-01 | $10.30M 10-K · filed 2021-03-01 | ||||
| 2019-09-28 | -$7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $600.00K derived: sum of 2 quarters · filed 2020-11-05 | $5.30M 10-Q · filed 2020-11-05 | |||||
| 2019-06-29 | $8.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $12.80M 10-Q · filed 2020-08-05 | ||||||
| 2019-03-30 | $4.70M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |